Stuart M. Grant Acquires 1,515,151 Shares of Eyenovia, Inc. (NASDAQ:EYEN) Stock

Eyenovia, Inc. (NASDAQ:EYEN) major shareholder Stuart M. Grant acquired 1,515,151 shares of Eyenovia stock in a transaction on Tuesday, July 2nd. The shares were bought at an average cost of $0.66 per share, with a total value of $999,999.66. Following the completion of the purchase, the insider now owns 10,914,153 shares in the company, valued at $7,203,340.98. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Eyenovia Stock Performance

Shares of EYEN stock traded up $0.03 during trading hours on Wednesday, reaching $0.77. 664,274 shares of the company’s stock were exchanged, compared to its average volume of 1,001,445. The company has a market cap of $41.39 million, a P/E ratio of -1.02 and a beta of 1.78. The company’s 50 day moving average is $0.74 and its two-hundred day moving average is $1.25. Eyenovia, Inc. has a 1 year low of $0.50 and a 1 year high of $2.60. The company has a debt-to-equity ratio of 3.72, a current ratio of 0.88 and a quick ratio of 0.66.

Eyenovia (NASDAQ:EYEN) last issued its earnings results on Wednesday, May 15th. The company reported ($0.18) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.18). The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $1.23 million. Equities research analysts anticipate that Eyenovia, Inc. will post -0.56 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $12.00 target price on shares of Eyenovia in a research note on Thursday, May 16th.

Institutional Investors Weigh In On Eyenovia

A number of institutional investors and hedge funds have recently modified their holdings of the company. Armistice Capital LLC grew its holdings in shares of Eyenovia by 41.8% in the 4th quarter. Armistice Capital LLC now owns 4,378,000 shares of the company’s stock worth $9,106,000 after acquiring an additional 1,290,979 shares during the period. Vanguard Group Inc. grew its holdings in shares of Eyenovia by 25.2% in the 1st quarter. Vanguard Group Inc. now owns 1,790,501 shares of the company’s stock worth $1,765,000 after acquiring an additional 360,924 shares during the period. BNP Paribas Financial Markets grew its holdings in shares of Eyenovia by 1,444.4% in the 1st quarter. BNP Paribas Financial Markets now owns 219,610 shares of the company’s stock worth $217,000 after acquiring an additional 205,390 shares during the period. PFG Investments LLC acquired a new stake in shares of Eyenovia in the 1st quarter worth approximately $69,000. Finally, Nations Financial Group Inc. IA ADV acquired a new stake in shares of Eyenovia in the 4th quarter worth approximately $84,000. Institutional investors and hedge funds own 25.84% of the company’s stock.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.